Clinical trial
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injection or Intravenous Infusion of SHR-7590 Injection in Healthy Chinese Participants and Participants With Moderate-to-Severe Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease)
NCT07758101 is registered in ClinicalTrials.gov with Guangdong Hengrui Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Injection or Intravenous Infusion of SHR-7590 Injection in Healthy Chinese Participants and Participants With Moderate-to-Severe Inflammatory Bowel Disease (Ulcerative Colitis and Crohn's Disease)
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- August 21, 2026
- Completion date
- December 31, 2027
- Enrollment
- 88 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
moderate-to-severe inflammatory bowel disease